Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.

Toxicological Research is a prominent academic journal dedicated to advancing the field of toxicology through rigorous exploration and innovative research. Published by the Korean Society of Toxicology, this journal serves as a vital resource for researchers, professionals, and students engaged in environmental science, pharmacology, and toxicology. With an ISSN of 1976-8257 and an E-ISSN of 2234-2753, Toxicological Research highlights significant findings and discussions in the realm of health, toxicology, and mutagenesis. Although not an open-access journal, it maintains a solid reputation as evidenced by its Q3 ranking in both health-related toxicology and general toxicology categories for 2023. The journal covers a broad spectrum of topics from fundamental research to applied toxicology and provides a unique platform for the dissemination of knowledge in a field that is increasingly relevant in today’s society. With an anticipated convergence period from 2008 to 2024, Toxicological Research continues to contribute vital insights to understanding the implications of toxic substances on health and the environment.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

Drug and Chemical Toxicology is a well-respected journal in the fields of toxicology, pharmacology, and public health, published by Taylor & Francis Ltd. Since its inception in 1978, this journal has diligently explored the effects and mechanisms of chemical exposures on health and the environment, fulfilling a crucial role in advancing scientific understanding and safeguarding public health. The journal is indexed across prestigious databases and features an impressive array of articles categorized within the Q2 and Q3 quartiles across various categories in 2023, reflecting its significance in Chemical Health and Safety as well as Environmental and Occupational Health disciplines. With an extensive reach and a focus on interdisciplinary research, Drug and Chemical Toxicology offers a rich repository of original research, reviews, and methodological advancements, catering to a diverse audience of researchers, professionals, and students dedicated to the betterment of safety and health standards. Although not an open-access publication, its articles are widely accessible to the academic community, ensuring that critical innovations and insights are shared for the greater good.

Advances in Pharmacological and Pharmaceutical Sciences is a premier open-access journal published by Hindawi Ltd. based in the United Kingdom. Established in 2020, the journal swiftly garnered attention for its commitment to disseminating high-quality research in the realms of pharmacology, toxicology, and pharmaceutical sciences. It holds a commendable impact with notable quartile rankings, including Q2 in both Organic Chemistry and Pharmacology, indicating its importance within these disciplines. By embracing an open-access model, the journal ensures that research findings are widely available, promoting increased visibility and collaboration among researchers, professionals, and students globally. With an ongoing convergence of insights projected through 2024, Advances in Pharmacological and Pharmaceutical Sciences aims to address critical issues and advancements in drug development and therapeutic practices, making it an invaluable resource for those at the forefront of scientific inquiry in pharmacology and related fields.

TOXICOLOGY IN VITRO is a premier journal published by PERGAMON-ELSEVIER SCIENCE LTD, focusing on the latest advancements in the field of toxicology, particularly through in vitro methodologies. With an ISSN of 0887-2333 and an E-ISSN of 1879-3177, this journal serves as a critical platform for researchers aiming to disseminate their findings in toxicology, emphasizing innovative approaches and applications in pharmacology and toxicology. Featuring a commendable impact factor and classified in the second quartile (Q2) for both Medicine (miscellaneous) and Toxicology in 2023, the journal holds a significant position within the academic community, ranking 41st out of 133 in the Toxicology category according to Scopus, representing the 69th percentile. Despite being a subscription-based publication, it continuously attracts submissions from leading scientists worldwide, fostering a vibrant exchange of scientific knowledge. Since its inception in 1987, TOXICOLOGY IN VITRO has consistently aimed to enhance understanding of toxicological challenges, making it an invaluable resource for professionals, students, and researchers dedicated to developing safer pharmaceuticals and understanding the biological pathways influenced by potential toxic agents.

CURRENT DRUG METABOLISM, published by Bentham Science Publishers Ltd, serves as a pivotal resource in the fields of Clinical Biochemistry and Pharmacology. With an ISSN of 1389-2002 and an E-ISSN of 1875-5453, this journal has carved a niche since its inception in 2000, offering in-depth research and reviews that bridge the gap between drug metabolism and its clinical applications. The journal finds itself positioned in the third quartile (Q3) for both Clinical Biochemistry and Pharmacology as of 2023, reflecting its significance within these scientific sectors, with Scopus rankings showcasing its role in advancing knowledge—rank #167 in Pharmacology and #66 in Clinical Biochemistry. Researchers and industry professionals are encouraged to contribute their findings, fostering a diverse platform that informs and inspires innovations in drug development and safety. While CURRENT DRUG METABOLISM operates under a traditional subscription model without open access, its rigorous peer-review process ensures the quality and integrity of the published work, making it indispensable for anyone engaged in drug research and biochemistry.

Current Research in Toxicology is a pioneering journal published by ELSEVIER that serves as a vital platform for disseminating cutting-edge research in the field of toxicology, spanning from biological impacts to pharmacological applications. With an ISSN of 2666-027X and an impressive Q2 ranking in key categories such as Applied Microbiology and Biotechnology, Health, Toxicology and Mutagenesis, and Toxicology, this journal underscores its commitment to high-quality research and significant contributions to the scientific community. Based in the Netherlands, Current Research in Toxicology aims to bridge the gap between academia and industry by providing rigorously peer-reviewed articles that cover a wide array of topics including novel methodologies, regulatory challenges, and emerging trends within the domain. The journal is accessible through various platforms, making it essential for researchers, professionals, and students eager to stay updated on the latest findings and advancements in toxicology. With a comprehensive focus on integrating theory with practical application, this journal is poised to influence future studies and policies in health and environmental science.

Current Pharmaceutical Analysis, published by Bentham Science Publishers Ltd, is a vital resource for professionals and researchers in the fields of Pharmaceutical Science, Biochemistry, and Molecular Medicine. Established in 2006, this peer-reviewed journal aims to provide a platform for the latest advancements and analytical methodologies in pharmaceutical research and drug development. Over the years, it has garnered attention for its rigorous scrutiny and contributions to the landscape of pharmacology, evidenced by its quartile placements in various categories, most notably Q3 in Pharmaceutical Science. Despite its current rankings placing it in the lower quartile in several disciplines, the journal remains an essential venue for both emerging and established researchers seeking to disseminate their findings. With the widespread accessibility of its articles, researchers, professionals, and students can engage with cutting-edge studies to foster innovation in pharmaceutical analysis. For access to the latest research contributions, readers can explore the digital archive and stay updated on pivotal discussions shaping the future of the pharmaceutical sciences.